Safinamide

Safinamide is a selective, non-dopaminergic adjunctive therapy for the treatment of Parkinson’s disease. It is a sodium channel blocker, and its mechanism of action involves selective inhibition of voltage-gated sodium channels, thereby reducing neuronal hyperexcitability in the basal ganglia.
The medication is used as an adjunct to levodopa-based therapy in patients experiencing motor fluctuations or dyskinesias (involuntary movements) associated with Parkinson’s disease. Safinamide works by reducing the motor complications without increasing the dopaminergic load, making it a valuable addition to the management of this chronic neurological disorder.
Safinamide should be taken orally, usually once a day, with or without food. It is important to follow the prescribed dosage and frequency to achieve the desired therapeutic effect. Common side effects may include dizziness, nausea, and falls. Patients should inform their healthcare provider if they experience any adverse reactions or worsening of symptoms.